REFERENCES
1. Annibali G, Scrocca I, Aranzulla TC, Meliga E, Maiellaro F, Musumeci G. "No-reflow" phenomenon: a contemporary review. J Clin Med. 2022;11:2233.
2. Kloner RA, Ganote CE, Jennings RB. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest. 1974;54:1496-508.
3. Study Group. The thrombolysis in myocardial infarction (TIMI) trial, phase I findings. N Engl J Med. 1985;312:932-6.
4. Carrick D, Haig C, Maznyczka AM, et al. Hypertension, microvascular pathology, and prognosis after an acute myocardial infarction. Hypertension. 2018;72:720-30.
5. Mehta RH, Harjai KJ, Cox D, et al. Primary Angioplasty in Myocardial Infarction (PAMI) Investigators. Clinical and angiographic correlates and outcomes of suboptimal coronary flow inpatients with acute myocardial infarction undergoing primary percutaneous coronary intervention. J Am Coll Cardiol. 2003;42:1739-46.
6. Rezkalla SH, Dharmashankar KC, Abdalrahman IB, Kloner RA. No-reflow phenomenon following percutaneous coronary intervention for acute myocardial infarction: incidence, outcome, and effect of pharmacologic therapy. J Interv Cardiol. 2010;23:429-36.
7. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in myocardial infarction (TIMI) trial, phase i: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation. 1987;76:142-54.
8. Gibson CM, Cannon CP, Murphy SA, et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 2000;101:125-30.
9. van't Hof AW, Liem A, Suryapranata H, Hoorntje JC, de Boer MJ, Zijlstra F; Zwolle Myocardial Infarction Study Group. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Circulation. 1998;97:2302-6.
10. Nijveldt R, van der Vleuten PA, Hirsch A, et al. Early electrocardiographic findings and MR imaging-verified microvascular injury and myocardial infarct size. JACC Cardiovasc Imaging. 2009;2:1187-94.
11. de Waha S, Patel MR, Granger CB, et al. Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an individual patient data pooled analysis from seven randomized trials. Eur Heart J. 2017;38:3502-10.
12. Galiuto L, Garramone B, Scarà A, et al. AMICI Investigators. The extent of microvascular damage during myocardial contrast echocardiography is superior to other known indexes of post-infarct reperfusion in predicting left ventricular remodeling: results of the multicenter AMICI study. J Am Coll Cardiol. 2008;51:552-9.
13. Konijnenberg LSF, Damman P, Duncker DJ, et al. Pathophysiology and diagnosis of coronary microvascular dysfunction in ST-elevation myocardial infarction. Cardiovasc Res. 2020;116:787-805.
14. Aggarwal P, Rekwal L, Sinha SK, Nath RK, Khanra D, Singh AP. Predictors of no-reflow phenomenon following percutaneous coronary intervention for ST-segment elevation myocardial infarction. Ann Cardiol Angeiol. 2021;70:136-42.
15. Nair Rajesh G, Jayaprasad N, Madhavan S, et al. Predictors and prognosis of no-reflow during primary percutaneous coronary intervention. Baylor Univ Med Cent Proc. 2019;32:30-3.
16. Bulluck H, Foin N, Tan JW, Low AF, Sezer M, Hausenloy DJ. Invasive assessment of the coronary microcirculation in peperfused ST-segment-elevation myocardial infarction patients: where do we stand? Circ Cardiovasc Interv. 2017;10:e004373.
17. Feher A, Chen SY, Bagi Z, Arora V. Prevention and treatment of no-reflow phenomenon by targeting the coronary microcirculation. Rev Cardiovasc Med. 2014;15:38-51.
18. Jaffe R, Dick A, Strauss BH. Prevention and treatment of microvascular obstruction-related myocardial injury and coronary no-reflow following percutaneous coronary intervention: a systematic approach. JACC Cardiovasc Interv. 2010;3:695-704.
19. Achkouty G, Dillinger JG, Sideris G, et al. Microcatheter-facilitated primary angioplasty in ST-segment elevation myocardial infarction. Can J Cardiol. 2018;34:23-30.
20. Balaban Y, Bektaş O, Bayramoğlu A, Gümrükçüoğlu HA, Kayışoğlu AH. Imaging behind occluded areas with an iatrogenic perforated balloon: a safe, practical, and simple new method of visualizing the distal lumen in total occlusion. J Interv Cardiol. 2017;30:544-9.
21. Akpek M, Sahin O, Sarli B, et al. Acute effects of intracoronary tirofiban on no-reflow phenomena in patients with ST-segment elevated myocardial infarction undergoing primary percutaneous coronary intervention. Angiology. 2015;66:560-7.
22. Correction to: 2023 ESC Guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2024;45:1145.
23. Aksu T, Guler TE, Colak A, et al. Intracoronary epinephrine in the treatment of refractory no-reflow after primary percutaneous coronary intervention: a retrospective study. BMC Cardiovasc Disord. 2015;15:10.
24. Afshar E, Samimisedeh P, Tayebi A, Shafiabadi Hassani N, Rastad H, Yazdani S. Efficacy and safety of intracoronary epinephrine for the management of the no-reflow phenomenon following percutaneous coronary interventions: a systematic-review study. Ther Adv Cardiovasc Dis. 2023;17:17539447231154654.
25. Navarese EP, Frediani L, Kandzari DE, et al. Efficacy and safety of intracoronary epinephrine versus conventional treatments alone in STEMI patients with refractory coronary no-reflow during primary PCI: The RESTORE observational study. Catheter Cardiovasc Interv. 2021;97:602-11.
26. Forman MB, Hou D, Jackson EK. Treating acute "no-reflow" with intracoronary adenosine in 4 patients during percutaneous coronary intervention. Tex Heart Inst J. 2008;35:439-46.
27. Fu XH, Fan WZ, Gu XS, et al. Effect of intracoronary administration of anisodamine on slow reflow phenomenon following primary percutaneous coronary intervention in patients with acute myocardial infarction. Chin Med J. 2007;120:1226-31. Available from: https://journals.lww.com/cmj/fulltext/2007/07020/Effect_of_intracoronary_administration_of.4.aspx. [Last accessed on 20 Dec 2024]
28. Huang RI, Patel P, Walinsky P, et al. Efficacy of intracoronary nicardipine in the treatment of no-reflow during percutaneous coronary intervention. Catheter Cardiovasc Interv. 2006;68:671-6.
29. Kobatake R, Sato T, Fujiwara Y, et al. Comparison of the effects of nitroprusside versus nicorandil on the slow/no-reflow phenomenon during coronary interventions for acute myocardial infarction. Heart Vessels. 2011;26:379-84.
30. Tesic MB, Stankovic G, Vukcevic V, Ostojic MC. The use of intracoronary sodium nitroprusside to treat no-reflow after primary percutaneous coronary intervention in acute myocardial infarction. Herz. 2010;35:114-8.
31. Wang L, Cheng Z, Gu Y, Peng D. Short-term effects of verapamil and diltiazem in the treatment of no reflow phenomenon: a meta-analysis of randomized controlled trials. Biomed Res Int. 2015;2015:382086.
32. Niu X, Zhang J, Bai M, Peng Y, Sun S, Zhang Z. Effect of intracoronary agents on the no-reflow phenomenon during primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: a network meta-analysis. BMC Cardiovasc Disord. 2018;18:3.
33. Darwish A, Frere AF, Abdelsamie M, Awady WE, Gouda M. Intracoronary epinephrine versus adenosine in the management of refractory no-reflow phenomenon: a single-center retrospective cohort study. Ann Saudi Med. 2022;42:75-82.
34. Maluenda G, Ben-Dor I, Delhaye C, et al. Clinical experience with a novel intracoronary perfusion catheter to treat no-reflow phenomenon in acute coronary syndromes. J Interv Cardiol. 2010;23:109-13.
35. Movahed MR. Successful distal administration of high doses of adenosine and nicardipine using export catheter for treatment of resistant no-reflow in a vein graft. Am J Cardiovasc Dis. 2022;12:53-5.
36. Movahed MR. Successful distal administration of high doses of adenosine has been reported using export or other catheters since 2008. Cardiovasc Revasc Med. 2023;53:75.
37. Cetin M, Kiziltunc E, Güven Cetin Z, Kundi H, Gulkan B, Cicekcioglu H. A practical method for no-reflow treatment. Case Rep Cardiol. 2016;2016:9596123.
38. Bashtawi Y, Almuwaqqat Z. Therapeutic hypothermia in STEMI. Cardiovasc Revasc Med. 2021;29:77-84.
39. Keeble TR, Karamasis GV, Noc M, et al. Effect of intravascular cooling on microvascular obstruction (MVO) in conscious patients with ST-elevation myocardial infarction undergoing primary PCI: results from the COOL AMI EU pilot study. Cardiovasc Revasc Med. 2019;20:799-804.
40. Mukherjee P, Jain M. Effect of ischemic postconditioning during primary percutaneous coronary intervention for patients with ST-segment elevation myocardial infarction: a single-center cross-sectional study. Ann Card Anaesth. 2019;22:347-52.
41. Thygesen K, Alpert JS, Jaffe AS, et al. Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth universal definition of myocardial infarction (2018). Circulation. 2018;138:e618-51.
42. Sianos G, Papafaklis MI, Daemen J, et al. Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden. J Am Coll Cardiol. 2007;50:573-83.
43. Kumar V, Sharma AK, Kumar T, Nath RK. Large intracoronary thrombus and its management during primary PCI. Indian Heart J. 2020;72:508-16.
44. Gibson CM, de Lemos JA, Murphy SA, et al. TIMI Study Group. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Circulation. 2001;103:2550-4.
45. Jolly SS, Cairns JA, Yusuf S, et al. TOTAL Investigators. Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med. 2015;372:1389-98.
46. Huang YX, Cao Y, Chen Y, et al. AngioJet rheolytic thrombectomy in patients with thrombolysis in myocardial infarction thrombus grade 5: an observational study. Sci Rep. 2022;12:5462.
47. Tashtish N, Chami T, Dong T, et al. Routine use of the "penumbra" thrombectomy device in myocardial infarction: a real-world experience-ROPUST study. J Interv Cardiol. 2022;2022:5692964.
48. Pradhan A, Bhandari M, Vishwakarma P, Sethi R. Deferred stenting for heavy thrombus burden during percutaneous coronary intervention for ST-elevation MI. Eur Cardiol. 2021;16:e08.
49. Custodio-Sánchez P, Damas-De Los Santos F, Peña-Duque MA, et al. Deferred versus immediate stenting in patients with ST - segment elevation myocardial infarction and residual large thrombus burden reclassified in the culprit lesion. Arch Cardiol Mex. 2018;88:432-40.
50. Araiza-Garaygordobil D, Arias-Mendoza A, González-Gutiérrez JC, et al. Coronary artery ectasia in ST-elevation myocardial infarction: prevalence and prognostic implications. Coron Artery Dis. 2022;33:671-3.
51. Matta AG, Yaacoub N, Nader V, Moussallem N, Carrie D, Roncalli J. Coronary artery aneurysm: a review. World J Cardiol. 2021;13:446-55.
52. Carrick D, Oldroyd KG, McEntegart M, et al. A randomized trial of deferred stenting versus immediate stenting to prevent no- or slow-reflow in acute ST-segment elevation myocardial infarction (DEFER-STEMI). J Am Coll Cardiol. 2014;63:2088-98.
53. Yokokawa T, Ujiie Y, Kaneko H, Seino Y, Kijima M, Takeishi Y. Lone aspiration thrombectomy without stenting for a patient with ST-segment elevation myocardial infarction associated with coronary ectasia. Cardiovasc Interv Ther. 2014;29:339-43.
54. Kawsara A, Núñez Gil IJ, Alqahtani F, Moreland J, Rihal CS, Alkhouli M. Management of coronary artery aneurysms. JACC Cardiovasc Interv. 2018;11:1211-23.
55. Núñez-Gil IJ, Terol B, Feltes G, et al. Coronary aneurysms in the acute patient: incidence, characterization and long-term management results. Cardiovasc Revasc Med. 2018;19:589-96.
56. Marschall A, Bastante T, Alfonso F. Double gender bias in spontaneous coronary artery dissection. Rev Esp Cardiol (Engl Ed). 2024;77:276.
57. Di Fusco SA, Rossini R, Zilio F, et al. Spontaneous coronary artery dissection: overview of pathophysiology. Trends Cardiovasc Med. 2022;32:92-100.
58. Saw J, Aymong E, Sedlak T, et al. Spontaneous coronary artery dissection: association with predisposing arteriopathies and precipitating stressors and cardiovascular outcomes. Circ Cardiovasc Interv. 2014;7:645-55.
59. Kidess GG, Brennan MT, Harmouch KM, Basit J, Chadi Alraies M. Spontaneous coronary artery dissection: a review of medical management approaches. Curr Probl Cardiol. 2024;49:102560.
61. Mehmedbegović Z, Ivanov I, Čanković M, et al. Invasive imaging modalities in a spontaneous coronary artery dissection: when "believing is seeing". Front Cardiovasc Med. 2023;10:1270259.
62. Saw J, Starovoytov A, Humphries K, et al. Canadian spontaneous coronary artery dissection cohort study: in-hospital and 30-day outcomes. Eur Heart J. 2019;40:1188-97.
63. Cerrato E, Giacobbe F, Quadri G, et al. DISCO Collaborators. Antiplatelet therapy in patients with conservatively managed spontaneous coronary artery dissection from the multicentre DISCO registry. Eur Heart J. 2021;42:3161-71.
64. Offen S, Yang C, Saw J. Spontaneous coronary artery dissection (SCAD): a contemporary review. Clin Cardiol. 2024;47:e24236.
65. Saw J, Starovoytov A, Aymong E, et al. Canadian spontaneous coronary artery dissection cohort study: 3-year outcomes. J Am Coll Cardiol. 2022;80:1585-97.
66. Main A, Saw J. Percutaneous coronary intervention for the treatment of spontaneous coronary artery dissection. Interv Cardiol Clin. 2019;8:199-208.
